Austin D.  Kim net worth and biography

Austin Kim Biography and Net Worth

Austin Kim is our Executive Vice President, General Counsel and Secretary and has been with Acadia since July 2018. From 2006 until 2017, Mr. Kim held several senior legal positions at Teva Pharmaceuticals, a global specialty pharmaceutical company. At Teva, Mr. Kim was most recently Vice President and Deputy General Counsel, Corporate/M&A, handling corporate and securities law matters, acquisitions and corporate development, capital markets transactions and corporate governance matters. Before joining Teva, Mr. Kim was Deputy General Counsel at IVAX Corporation, a global generic pharmaceutical company, which was acquired by Teva in 2006. Earlier in his career, Mr. Kim was a senior lawyer at Transamerica Corporation, practiced law at Pillsbury, Madison & Sutro and clerked for Judge Vaughn Walker of the United States District Court, Northern District of California. Mr. Kim received his J.D. degree from Columbia University School of Law and his A.B. in English Literature and Economics from Stanford University.

What is Austin D. Kim's net worth?

The estimated net worth of Austin D. Kim is at least $853,598.20 as of January 8th, 2024. Mr. Kim owns 46,901 shares of ACADIA Pharmaceuticals stock worth more than $853,598 as of March 28th. This net worth evaluation does not reflect any other assets that Mr. Kim may own. Learn More about Austin D. Kim's net worth.

How do I contact Austin D. Kim?

The corporate mailing address for Mr. Kim and other ACADIA Pharmaceuticals executives is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. ACADIA Pharmaceuticals can also be reached via phone at (858) 558-2871 and via email at [email protected]. Learn More on Austin D. Kim's contact information.

Has Austin D. Kim been buying or selling shares of ACADIA Pharmaceuticals?

Austin D. Kim has not been actively trading shares of ACADIA Pharmaceuticals over the course of the past ninety days. Learn More on Austin D. Kim's trading history.

Who are ACADIA Pharmaceuticals' active insiders?

ACADIA Pharmaceuticals' insider roster includes Laura Brege (Director), Stephen Davis (CEO), James Kihara (Insider), Austin Kim (EVP), Elena Ridloff (CFO), Mark Schneyer (CFO), Srdjan Stankovic (President), and Brendan Teehan (COO). Learn More on ACADIA Pharmaceuticals' active insiders.

Are insiders buying or selling shares of ACADIA Pharmaceuticals?

During the last year, ACADIA Pharmaceuticals insiders bought shares 1 times. They purchased a total of 209,053 shares worth more than $5,312,036.73. During the last year, insiders at the biopharmaceutical company sold shares 35 times. They sold a total of 319,071 shares worth more than $7,885,816.65. The most recent insider tranaction occured on March, 27th when COO Brendan Teehan sold 5,140 shares worth more than $92,006.00. Insiders at ACADIA Pharmaceuticals own 27.5% of the company. Learn More about insider trades at ACADIA Pharmaceuticals.

Information on this page was last updated on 3/27/2024.

Austin D. Kim Insider Trading History at ACADIA Pharmaceuticals

See Full Table

Austin D. Kim Buying and Selling Activity at ACADIA Pharmaceuticals

This chart shows Austin D. Kim's buying and selling at ACADIA Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ACADIA Pharmaceuticals Company Overview

ACADIA Pharmaceuticals logo
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $18.20
Low: $17.73
High: $18.20

50 Day Range

MA: $23.85
Low: $17.79
High: $28.15

2 Week Range

Now: $18.20
Low: $17.56
High: $33.99

Volume

1,701,366 shs

Average Volume

1,879,943 shs

Market Capitalization

$3.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4